Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
Other Sizes |
|
Purity: ≥98%
Fluoxetine HCl (LY-110140; Lilly-110140; Prozac, Sarafem, Animex-On, Pulvules, Eufor, Portal), the HCl salt of fluoxetine, is a potent and selective serotonin-reuptake inhibitor (SSRI) at the neuronal membrane with anti-depressant activity. It can be used to treat premenstrual dysphoric disorder, bulimia nervosa, panic disorder, depression, and obsessive-compulsive disorder. In people 65 years of age and older, fluoxetine may reduce the risk of suicide. Premature ejaculation has also been treated with fluoxetine. It is consumed orally.
Targets |
5-HT
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
The membrane currents induced by serotonin (5-hydroxytryptamine; 5HT) were inhibited by micromolar concentrations of fluoxetine (Prozac) in Xenopusoocytes expressing either cloned 5HT2C receptors or 5HT receptors. The IC50 of fluoxetine was approximately 20 μM for responses elicited by 1 μM 5-HT. Moreover, [3H]5HT binding to 5HT receptors in rat cortex membranes and [3H]5HT binding to 5HT2C receptors expressed in HeLa cells were both inhibited by fluoxetine, with Ki values of ≈65–97 nM and ≈ 56 μM, respectively. The administration of fluoxetine prevented the inescapable shock (IS)-induced downregulation of hippocampal cell proliferation, which led to a behaviorally hopeless state. In rat adult hippocampal dentate gyrus, fluoxetine augmented the number of proliferating cells. The prelimbic cortex's proliferating cell count was also elevated by fluoxetine. Neutrophils matured more quickly when taking fluoxetine. LTP in the dentate gyrus was enhanced by fluoxetine in a neurogenesis-dependent manner. In prefrontal cortex, fluoxetine increased norepinephrine and dopamine extracellular levels, but not other selective serotonin uptake inhibitors like citalopram, fluvoxamine, paroxetine, and sertraline. Fluoxetine generated significant and long-lasting increases in dopamine and norepinephrine extracellular concentrations following acute systemic administration.
|
|
Animal Protocol |
|
|
References |
Molecular Formula |
C17H19CLF3NO
|
|
---|---|---|
Molecular Weight |
345.79
|
|
Exact Mass |
345.11
|
|
Elemental Analysis |
C, 59.05; H, 5.54; Cl, 10.25; F, 16.48; N, 4.05; O, 4.63
|
|
CAS # |
56296-78-7
|
|
Appearance |
Solid powder
|
|
SMILES |
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl
|
|
InChi Key |
GIYXAJPCNFJEHY-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C17H18F3NO.ClH/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20;/h2-10,16,21H,11-12H2,1H3;1H
|
|
Chemical Name |
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2922.39.4500
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8919 mL | 14.4596 mL | 28.9193 mL | |
5 mM | 0.5784 mL | 2.8919 mL | 5.7839 mL | |
10 mM | 0.2892 mL | 1.4460 mL | 2.8919 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03826875 | Recruiting | Drug: Fluoxetine Drug: Placebo |
Stroke Hemorrhagic Depression |
University of Washington | March 1, 2019 | Phase 2 |
NCT05634707 | Recruiting | Drug: Fluoxetine Drug: Temozolomide |
Primary Brain Tumor Brain Tumor, Recurrent |
Duke University | August 5, 2023 | Early Phase 1 |
NCT03228732 | Recruiting | Drug: Fluoxetine Drug: Fluoxetine and DHEA |
Type 1 Diabetes Mellitus | University of Maryland, Baltimore |
December 19, 2017 | Early Phase 1 |
NCT05976347 | Not yet recruiting | Drug: Fluoxetine 20 MG Drug: Duloxetine 30 MG/td> | Depression | Wake Forest University Health Sciences |
February 2024 | Phase 4 |
NCT06225011 | Not yet recruiting | Drug: Fluoxetine | Colorectal Adenocarcinoma | Jonsson Comprehensive Cancer Center |
June 1, 2024 | Phase 1 |
Chronic but not subchronic fluoxetine treatment increases cell proliferation but not the number of DCX+ immature granule cells in the dentate gyrus. J Neurosci . 2008 Feb 6;28(6):1374-84. td> |
Chronic but not subchronic fluoxetine stimulates dendritic maturation of DCX+ cells. J Neurosci . 2008 Feb 6;28(6):1374-84. td> |
Chronic but not subchronic fluoxetine enhances dendritic complexity of DCX+ cells. J Neurosci . 2008 Feb 6;28(6):1374-84. td> |
Effects of haloperidol (1 mg/kg, s.c.) and fluoxetine (10 mg/kg, s.c.) alone and in combination on [5-HT]ex (A), [DA]ex (B), and [NE]ex (C) in the rat prefrontal cortex. Neuropsychopharmacology . 2000 Sep;23(3):250-62. td> |
Effects of MDL 100907 (1 mg/kg, s.c.) and fluoxetine (10 mg/kg, s.c.) alone and in combination on [5-HT]ex (A), [DA]ex (B), and [NE]ex (C) in the rat prefrontal cortex. Neuropsychopharmacology . 2000 Sep;23(3):250-62. td> |
Higher concentrations of fluoxetine have no significant impact on proliferation and cell cycle progression of MDA-MB-231 breast cancer cells. Sci Rep . 2021 Jan 13;11(1):1250. td> |
Fluoxetine and sertraline marginally increase glucose uptake in SK-OV-3 cells. Sci Rep . 2021 Jan 13;11(1):1250. td> |